A multicenter clinical evaluation of the Clot Signature Analyzer

Area of Science:

• Hematology
• Diagnostic Assays
• Hemostasis Research

Background:

• The Clot Signature Analyzer (CSA) is a novel instrument designed for global hemostasis assessment.
• It functions as a screening assay utilizing non-anticoagulated whole blood.
• The CSA generates three key measurements: platelet hemostasis time (PHT), clot time (CT), and collagen-induced thrombus formation (CITF).

Purpose of the Study:

• To establish normal reference ranges for CSA measurements.
• To evaluate the diagnostic performance of the CSA in patients with known hemostatic disorders.
• To compare CSA performance in patient cohorts versus healthy control subjects.

Main Methods:

• A multi-institutional study involving four participating centers.
• Each institution established its own normal reference ranges for CSA parameters.
• Patients with well-characterized hemostatic disorders and healthy controls were enrolled and analyzed.

Main Results:

• Normal ranges showed similarity across institutions, with statistically significant differences noted.
• The study analyzed 108 patients with various bleeding disorders, including von Willebrand disease (VWD), coagulation factor deficiencies, and platelet function defects, plus patients on anticoagulation.
• CSA detected at least one abnormality in 89% of these patients, demonstrating high sensitivity.
• Of 116 normal subjects, 89% fell within the established normal ranges.

Conclusions:

• The Clot Signature Analyzer (CSA) demonstrates significant potential as a sensitive screening tool for a wide spectrum of bleeding disorders.
• The assay effectively identifies hemostatic abnormalities in patients with conditions such as VWD and coagulation factor deficiencies.
• CSA performance suggests its utility in clinical settings for the initial assessment of hemostatic function.